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NPC1 regulates the distribution of
phosphatidylinositol 4-kinases at Golgi and
lysosomal membranes
Candice Kutchukian1,† , Oscar Vivas1,†,‡ , Maria Casas1, Julia G Jones1, Scott A Tiscione1,
2, Daniel S Ory3, Rose E Dixon1 & Eamonn J Dickson1,*
Sergi Simo

Abstract
Cholesterol and phosphoinositides (PI) are two critically important
lipids that are found in cellular membranes and dysregulated in many
disorders. Therefore, uncovering molecular pathways connecting
these essential lipids may offer new therapeutic insights. We report
that loss of function of lysosomal Niemann-Pick Type C1 (NPC1)
cholesterol transporter, which leads to neurodegenerative NPC
disease, initiates a signaling cascade that alters the cholesterol/phosphatidylinositol 4-phosphate (PtdIns4P) countertransport cycle
between Golgi-endoplasmic reticulum (ER), as well as lysosome-ER
membrane contact sites (MCS). Central to these disruptions is
increased recruitment of phosphatidylinositol 4-kinases—PI4KIIa and
PI4KIIIb—which boosts PtdIns4P metabolism at Golgi and lysosomal
membranes. Aberrantly increased PtdIns4P levels elevate constitutive
anterograde secretion from the Golgi complex, and mTORC1 recruitment to lysosomes. NPC1 disease mutations phenocopy the transporter loss of function and can be rescued by inhibition or knockdown
of either key phosphoinositide enzymes or their recruiting partners. In
summary, we show that the lysosomal NPC1 cholesterol transporter
tunes the molecular content of Golgi and lysosome MCS to regulate
intracellular trafficking and growth signaling in health and disease.
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Introduction
Phosphoinositides are a family of eight phospholipids that define
membrane identity by transducing extracellular signals, controlling

ion channel function, facilitating cell movement, and orchestrating
intracellular trafficking (reviewed, (De Matteis & Godi, 2004; Balla,
2013; Hille et al, 2015; Dickson & Hille, 2019). Given their importance in coordinating these fundamental cellular events, it is
perhaps not surprising that disease mutations or changes in expression of phosphoinositide metabolizing enzymes have been implicated in viral replication (Bishe et al, 2012; Sasaki et al, 2012;
McPhail et al, 2019), devastating developmental disorders (Staiano
et al, 2015), cancer (Bunney & Katan, 2010; Thapa et al, 2016;
Fruman et al, 2017; Waugh, 2019), and neurodegenerative diseases
(Leissring et al, 1999; Staiano et al, 2015; Vivas et al, 2019). Thus,
understanding mechanisms that regulate and control phosphoinositides is essential from both a cell biological and clinical perspective.
At the Golgi complex, a single mono-phosphorylated species called
phosphatidylinositol 4-phosphate (PtdIns4P) predominates and is
required for regulated Golgi vesicular trafficking events, signaling and
metabolic function, and structural integrity. Golgi PtdIns4P is synthesized by the ATP-dependent phosphorylation of phosphatidylinositol
(PtdIns) by Golgi-targeted lipid kinases, termed phosphatidylinositol
4-kinases (PI4K). Four different PI 4-kinases are expressed in most
human cells; the type I PI 4-kinase IIIa (PI4KIIIa) and PI 4-kinase IIIb
(PI4KIIIb) enzymes and the structurally distinct type II PI 4-kinases,
PI4KIIa and PI4KIIb (Balla & Balla, 2006). At the Golgi complex, the
PI4KIIIb and PI4KIIa isoforms are the major enzymes responsible for
regulating Golgi PtdIns4P-dependent events. Dysregulation of Golgi
PtdIns4P metabolism and the PtdIns4P protein interactome features in
many cancers and is often associated with tumor progression (Waugh,
2019). Despite evidence linking altered PtdIns4P in cancers, information regarding dysfunctional PtdIns4P metabolism in neurodegenerative diseases is lacking.
In addition to de novo lipid synthesis, target organelle
membranes can have lipids transported to them from donor
membranes. This form of lipid transport occurs at regions where
organelle membranes are less than 20 nm apart, termed membranes
contact sites (MCS), and is facilitated by lipid transfer proteins. At
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MCS between trans-Golgi network (TGN) and endoplasmic reticulum
(ER) (Mesmin et al, 2013), or between the lysosome and ER (Lim
et al, 2019), oxysterol-binding protein (OSBP) mediates the transport
of PtdIns4P down its concentration gradient to the ER, fueling the
countertransport cycle of cholesterol against its steep concentration
gradient (Mesmin et al, 2013). This cholesterol/PtdIns4P exchange
contributes to the establishment of a cholesterol gradient between
organelles of the secretory pathway and is essential for protein trafficking to the plasma membrane (PM) (Peresse et al, 2020) and
mTORC1 recruitment to lysosomes (Lim et al, 2019). At ER-TGN
MCS, PI4KIIa and PI4KIIIb, as well as an ER PtdIns4P phosphatase
(SAC1), maintain the TGN PtdIns4P gradient to perpetuate this
exchange cycle (Mesmin et al, 2013; Zewe et al, 2018; Mesmin et al,
2019; Venditti et al, 2019). Likewise, SAC1 and OSBP have also been
identified as being essential for cholesterol/PtdIns4P exchange at ERlysosome MCS. Despite this knowledge, essential information is still
unknown, such as (i) the molecular identity of the PI4K that generates
PtdIns4P for ER-lysosome lipid transport and (ii) if this molecular
choreography is disrupted during pathophysiological conditions.
Here, we report that in Niemann-Pick Type C1 (NPC1) disease, a
pathological neurodegenerative disorder of altered cholesterol homeostasis, there is a rearrangement of molecular components of the cholesterol/PtdIns4P cycle. Specifically, we demonstrate that disease mutations
or loss of lysosomal NPC1 function leads to the aberrant accumulation of
PtdIns4P on Golgi and lysosomal membranes. Underlying altered distribution of PtdIns4P is cholesterol-dependent transcriptional changes in
the recruitment machinery of PI4K metabolizing enzymes. Consequences of altered Golgi and lysosomal PtdIns4P are enhanced anterograde trafficking to the PM and mTORC1 recruitment to lysosomes,
respectively. We propose that the lysosomal NPC1 cholesterol transporter tunes the molecular elements of both ER-TGN and ER-lysosome
MCS in health and disease to regulate trafficking and growth signaling.

Results
Loss of NPC1 function leads to increased Golgi and lysosomal
PtdIns4P levels
Niemann-Pick Type C1 (NPC1) is a lysosomal cholesterol transporter that facilitates the egress of cholesterol across the lysosome
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lumen to other cellular membranes. Inhibition, loss of function,
or disease mutations in NPC1 cause the accumulation of lysosomal cholesterol and altered cellular cholesterol homeostasis
(Appendix Fig S1A–C). Given the interdependent relationship
between cholesterol and PtdIns4P levels at MCS (Antonny et al,
2018; Mesmin et al, 2019), we hypothesized that loss of NPC1 function may lead to changes in cellular PtdIns4P levels. To test this
hypothesis, we quantified changes in the distribution of the
PtdIns4P biosensor P4M (Hammond et al, 2014) under three different NPC1 conditions: inhibition, knockout, and disease mutations. Inhibition of NPC1 using the specific inhibitor U18666A (Lu
et al, 2015) (U18) resulted in the significant accumulation of P4M at
perinuclear and endolysosomal regions in tsA201 cells (Fig 1A and
B) and neurons (Fig 1C and D). To confirm that U18-mediated
increases in cellular PtdIns4P were not due to some off-target effect
of the U18 compound, we analyzed the distribution of the P4M
biosensor in NPC1/ cells. Similar to pharmacological inhibition of
NPC1, its genetic knockout also resulted in similar PtdIns4P accumulation (Appendix Fig S1D and E). Finally, to determine if elevated
PtdIns4P levels are a cellular phenotype of NPC disease, we
expressed the P4M biosensor in patient fibroblasts that harbor the
most common NPC1 mutation (NPC1I1061T). Similar to U18-treated
and NPC1/, NPC1I1061T patient fibroblasts had significantly
increased PtdIns4P levels in perinuclear and endolysosomal regions
(Appendix Fig S1F and G). To characterize the subcellular localization of PtdIns4P, we coexpressed P4M with either trans-Golgi
network (TGN38-CFP) or lysosomal (LAMP1-RFP) markers in
patient fibroblasts. Quantitative analyses revealed that PtdIns4P
significantly increased at both TGN (Fig 1E–G) and lysosome
membranes (Fig 1H–J and Appendix Fig S1H–J). Increases in Golgi
PtdIns4P occurred independently of changes in gross Golgi structure
as super-res imaging (resolution ~ 120 nm) of Giantin and TGN46
revealed no significant differences in TGN area from fibroblasts or
U18-treated cells (Appendix Fig S1K–M).
To endorse P4M biosensor data, we also quantitatively analyzed
phosphoinositide levels across different brain regions of a
NPC1I1061T murine model that faithfully recapitulates the most
common phenotypes of the human disease (Praggastis et al, 2015).
Mass spectrometry lipid analysis of the phosphoinositide composition from four different NPC1I1061T brain regions (mid-brain,
hippocampus, cortex, and cerebellum) confirmed significant

Figure 1. PtdIns4P accumulates in Golgi and lysosomal compartments following loss of NPC1 function.
A
B
C
D
E
F
G
H
I
J
K

Confocal images of live control (top) and U18-treated (bottom) tsA201 cells expressing P4M-YFP. Black and orange rectangles show expanded views of PtdIns4P in
perinuclear and endo/lysosomal compartments, respectively.
Quantification of perinuclear P4M-YFP mean fluorescence intensity normalized to the cytoplasm. Control: n = 19; U18: n = 16.
Confocal images of control and U18-treated hippocampal neurons transfected with P4M-YFP. The inset panels show expanded views of PtdIns4P in perinuclear regions.
Quantification of perinuclear P4M-YFP mean fluorescence intensity normalized to the cytoplasm. Control: n = 11; U18: n = 10.
Control (top) and NPC1I1061T (bottom) patient fibroblasts transfected with P4M-YFP (left), TGN38-CFP, and merge (right). Black rectangles show expanded views of
PtdIns4P in TGN38 regions. Dashed white lines were used for intensity profile analysis (F).
Line scan analysis taken from white dashed lines in (E) showing intensity changes of P4M and TGN38 signal from control (top) and NPC1I1061T (bottom) cells.
Quantification of P4M signal in TGN38 region (P4MTGN38). Control: n = 12; NPC1I1061T: n = 19.
Same as (E) only LAMP1-RFP expressed instead of TGN38.
Same as (F) only LAMP1 instead of TGN38.
Quantification of P4M signal in LAMP1 regions (P4MLAMP1). Control: n = 14; NPC1I1061T: n = 16.
Heat map of PtdIns, PtdInsP and PtdInsP2 levels from 4 different murine brain regions. The colors from green to red indicate the relative contents of lipid isoforms in
different brain regions from NPC1I1061T mice relative to wild-type brains; n = 3 for both WT and NPC1I1061T animals.

Data information: Data are all expressed as mean  SEM from individual cells. *P < 0.05; **P < 0.01; ****P < 0.0001 with unpaired t-test.
Source data are available online for this figure.
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elevations in global PtdInsP levels relative to wild-type age and sexmatched littermates (Fig 1K). Consistent with NPC1 global brain
expression, the increase of PtdInsP in NPC1I1061T brains was not
region-specific, with PtdInsP levels significantly elevated across
each area, suggesting that the loss of NPC1 function alters the levels
of PtdInsP regardless of region. Furthermore, increases in PtdInsP
were paralleled by decreases in PtdIns and PtdInsP2 (Vivas et al,
2019), confirming broader control of phosphoinositide species by
NPC1. Collectively, these data support a link between the lysosome
NPC1 protein and regulation of Golgi and Lysosome PtdIns4P levels.
NPC1 regulates the molecular elements of ER-TGN membrane
contact sites
At ER-TGN and ER-Lysosome MCS, OSBP (Mesmin et al, 2013; Lim
et al, 2019), VAPA (Peretti et al, 2008; Lim et al, 2019), and SAC1
(Zewe et al, 2018; Lim et al, 2019) serve as important regulators of
PtdIns4P homeostasis (Fig 2A). Thus, we tested if loss of NPC1
function can tune the expression and localization of ER-TGN MCS
proteins to potentially account for the changes in subcellular
PtdIns4P distribution.
Western blot analysis from U18-treated cells revealed that total
cellular protein levels of OSBP were not significantly different from
control cells (Fig 2B). Subsequent super-resolution immunofluorescence analysis from tsA201 cells treated with U18 revealed that
although cellular protein levels were similar, significantly more
OSBP localized to TGN46 regions (Fig 2C and D). Similar results
were obtained from NPC1I1061T patient cells (Fig EV1A and B) and
U18-treated neurons (Fig 2E and F) compared to appropriate
controls. OSBP is recruited to ER-TGN junctions through dual interactions of its PH domain with Golgi PtdIns4P and binding of its
FFAT motif to the type II ER membrane protein VAPA (Levine &
Munro, 2002; Loewen et al, 2003). With this in mind, we asked if
VAPA also accumulates in Golgi regions of cells lacking NPC1?
Immunofluorescence analysis determined that, similar to OSBP,
VAPA accumulated at the TGN in U18-treated tsA201 cells (Fig 2G
and H), at the Golgi of NPC1I1061T patient cells (Fig EV1C and D),
and perinuclear regions of NPC1/ cells (Fig EV1E and F).

Candice Kutchukian et al

Parallel increases in PtdIns4P (Fig 1), OSBP (Fig 2C–F), and
VAPA (Fig 2G and H) at ER-TGN MCS have been observed under
circumstances of OSBP inhibition (Mesmin et al, 2017). Therefore,
we tested if OSBP-mediated PtdIns4P transport kinetics are altered
following loss of NPC1 function. To test this hypothesis, we first
transfected tsA201 cells with GFP-P4M, to monitor TGN PtdIns4P,
and transiently treated cells with a specific inhibitor of PI4KIIIb
activity (PIK93 (Toth et al, 2006)). PI4KIIIb is responsible for local
PtdIns4P production in the vicinity of OSBP (Mesmin et al, 2017);
thus, inhibiting PI4KIIIb, while monitoring P4M intensity at the
TGN, allows us to indirectly track the rate of PtdIns4P molecules
consumed by OSBP. Transient application of PIK93 caused a rapid
and reversible drop in P4M intensity at the Golgi from both control
and U18-treated tsA201 cells (Fig EV1G and H). Comparison of vehicle and U18-treated cells revealed that loss of NPC1 function results
in both a significantly larger and faster loss of PtdIns4P. This
decrease in PtdIns4P biosensor intensity may represent PtdIns4P
transferred from the TGN to the ER where it is subsequently
degraded by the ER lipid phosphatase SAC1. To more directly
measure OSBP kinetics following loss of NPC1 function, we also
transfected tsA201 cells with GFP-P4M and treated with a selective
OSBP inhibitor (OSW-1 (Burgett et al, 2011)). Time series analysis
revealed that loss of OSBP function resulted in faster recruitment of
GFP-P4M to the TGN compared to vehicle controls (Fig EV1I and J).
Together, these data provide evidence that OSBP-mediated transport
of PtdIns4P is accelerated and therefore unlikely to be directly facilitating increases in PtdIns4P following NPC1 loss of function.
Maintenance of the OSBP transfer cycle requires a steep PtdIns4P
gradient to be conserved across ER-TGN MCS. This chemical gradient is conserved through the enzymatic actions of SAC1, which
degrades its PtdIns4P substrate on ER membranes (Fig 2A). In light
of increased TGN PtdIns4P, VAPA, and OSBP levels in cells lacking
functional NPC1 (Figs 1 and 2C–H), we asked if SAC1 at ER-TGN
MCS is also sensitive to changes in NPC1 function. Measurement of
SAC1 protein levels revealed no significant difference between
control and NPC1I1061T patient cells (Fig 2I). Overnight inhibition of
NPC1 in GFP11-SAC1 cells (endogenous SAC1 tagged with a GFP
(Zewe et al, 2018)) caused a significant redistribution of SAC1 to

Figure 2. NPC1 regulates the contents of ER-TGN membrane contact sites.
A Diagram of the molecular elements within ER-TGN membrane contact sites.
B Representative Western blot for OSBP in control and U18-treated tsA201 cells. Protein levels were determined by densitometry with b-actin normalization. Each
point (n = 3) represents protein levels from U18-treated cells normalized to control bands.
C Confocal images of control and U18-treated tsA201 cells fixed and stained for OSBP (left), TGN46 (middle), and merge (right). Black rectangles show expanded views
of OSBP and TGN46 regions.
D Quantification of OSBP signal in TGN46 regions (OSBPTGN46). Control: n = 40; U18: n = 39.
E Confocal images of control and U18-treated hippocampal neurons fixed and stained for OSBP. Dashed black lines represent the outline of each neuron.
F Quantification of OSBP in perinuclear region of control and U18-treated neurons. Control: n = 10; U18: n = 14.
G Confocal images of control and U18-treated tsA201 cells fixed and stained for VAPA (left), TGN46 (middle), and merge (right). Black rectangles show expanded views
of VAPA and TGN46 regions.
H Quantification of VAPA signal in TGN46 regions (VAPATGN46). Control: n = 44; U18: n = 44.
I Representative Western blot of SAC1 in control and U18-treated tsA201 cells. Protein levels were normalized to b-actin, n = 4.
J Confocal images of control and U18-treated GFP11-SAC1 HEK293 cells (top) and control and NPC1I1061T patient fibroblasts immunolabeled with anti-SAC1 antibody
(bottom). Insets show an enlarged view of SAC1 centered on a perinuclear region.
K Quantification analyses of GFP11-SAC1 (top; Control: n = 10; U18: n = 10) and anti-SAC1 (bottom; Control: n = 7; NPC1I1061T: n = 8) mean fluorescence intensities in
Golgi normalized to the cytoplasm.
Data information: Data are all expressed as mean  SEM from individual cells, and all statistical analyses were conducted using unpaired t-test with *P < 0.05;
**P < 0.01; ***P < 0.001; and ****P < 0.0001.
Source data are available online for this figure.
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Golgi regions (Fig 2J–K). This result is underscored by immunofluorescence analysis of endogenous SAC1 in NPC1I1061T patient cells
that revealed a similar accumulation of SAC1 at Golgi regions
(Fig 2J and K; Appendix Fig S2A–C). SAC1’s precise localization at
ER-TGN regions is controversial with some groups offering evidence
for SAC1 being localized in ER membranes and acting in cis
(Mesmin & Bigay, 2013; Zewe et al, 2018) or trans (Venditti et al,
2019) to dephosphorylate TGN PtdIns4P, while others have
proposed SAC1 can traffic to Golgi membranes under different
growth conditions to regulate Golgi PtdIns4P levels (Blagoveshchenskaya et al, 2008). Using super-resolution microscopy, we quantified
the relative distribution of endogenous SAC1 at the ER and TGN
from live vehicle control or U18-treated HEK cells. Appendix Fig
S2A–C demonstrates that inhibition of NPC1 leads to an increase in
SAC1 at TGN46-positive regions (SAC1TGN46) that occurs in the
absence of any changes to SAC1 at SEC61b-positive regions
(SAC1SEC61b). To further examine if loss of NPC1 function can alter
the gross distribution of ER and TGN, we immunostained GFP11SEC61b HEK cells (Zewe et al, 2018) and COS7 cells (expressing
mCherry-SEC61b) for TGN46. Analysis of SEC61b and TGN38 fluorescent signals revealed no significant changes in overlapping pixels
or TGN area following U18 treatment (Appendix Fig S2D–G). Thus,
at this resolution (~ 120 nm), given no clear alterations in ER-TGN
distribution, we suggest it is the redistribution of SAC1 to ER-TGN
MCS, rather than gross changes to ER-MCS architecture that underlies increases in SAC1. In addition to redistribution of SAC1 at
ER-TGN MCS, we also observed increased recruitment of SAC1 at
ER-Lysosome MCS (Appendix Fig S2H–J), supporting a role for
SAC1 in maintaining the step PtdIns4P gradient between ER and
other membranes. Collectively, these data demonstrate that NPC1
has the ability to influence elements within ER-TGN MCS but does
not provide a direct explanation as to why TGN PtdIns4P levels are
increased in NPC1 disease.
Inhibition or disease mutations in NPC1 recruit PI4K enzymes to
Golgi and Lysosome membranes
Given that NPC1-mediated changes in VAPA, OSBP, and SAC1
distribution are likely positioned downstream of increases in
PtdIns4P levels, we next asked if loss of NPC1 function more
directly influences PtdIns4P-metabolizing enzymes. Cellular
PtdIns4P levels are controlled in space and time through the

Candice Kutchukian et al

enzymatic activities of the PI4K family of enzymes (PI4KIIa,
PI4KΙΙb, PI4KΙIIa, PI4KΙΙΙb; Fig 3A). Increases in catalytic activity
and/or membrane localization of PI4K lipid enzymes would represent the most intuitive route to increase PtdIns4P levels through the
phosphorylation of phosphatidylinositol (PtdIns; Fig 3A). Of the
four PI4K family members, PI4KIIa and PI4KΙΙΙb have been demonstrated to localize to Golgi and lysosome membranes at steady state
(Weixel et al, 2005; Sridhar et al, 2013). To assess if a simple
increase in the abundance of these PI4K enzymes is responsible for
elevated PtdIns4P levels, cell lysates from U18-treated tsA201 cells
were immunoblotted for PI4KIIa and PI4KΙΙΙb (Fig 3B). Western blot
analysis determined no changes in the total cellular protein expression of either PI4KIIa or PI4KΙΙΙb enzymes, suggesting that a simple
increase in protein amount is unlikely to account for the elevated
TGN and lysosomal PtdIns4P levels.
Next, we tested the hypothesis that increased recruitment of PI4K
enzymes may underlie the elevations in Golgi or Lysosome PtdIns4P
levels following NPC1 inhibition, knockout, or mutation. To this
end, we expressed fluorescently tagged PI4K enzymes and quantified
their cellular distribution in NPC1 patient cells, U18-treated tsA201
cells, and neurons. PI4KΙΙb and PI4KΙΙΙa had a similar subcellular distribution across control and U18-treated tsA201 cells
(Appendix Fig S3A and B) and thus were excluded from further analysis. In contrast, quantification of overexpressed PI4KIIa and
PI4KΙΙΙb revealed significantly increased levels of both enzymes at
perinuclear regions in U18-treated tsA201 cells relative to control
(Fig 3C and D). To more precisely determine if these perinuclear
increases in enzyme localization reflect increases at the TGN, we
fixed control and U18-treated tsA201 cells before staining for endogenous PI4KIIa and PI4KΙΙΙb levels and TGN46. Super-resolution imaging analysis revealed that the fraction of PI4KIIa (Fig 3E and F) and
PI4KΙΙΙb (Fig 3G and H) overlapping with TGN46 significantly
increased following loss of NPC1 function. Similar results were
observed with a second more general Golgi marker; Giantin
(Appendix Fig S4A–D). These observations were also consistent for
neurons (Fig 3I and J), NPC1/ cells (Appendix Fig S3G–J), and
NPC1I1061T patient fibroblasts (Appendix Figs S3C–F and S4E–L).
In addition to increased PI4KIIa and PI4KΙΙΙb levels at Golgi
membranes, we also observed that fluorescently tagged PI4KIIa and
PI4KΙΙΙb preferentially localized to endolysosomal locations in
NPC1I1061T patient cells (Fig EV2A–D). This distribution is consistent with increased lysosomal PtdIns4P observed following loss of

Figure 3. PI4KIIa and PI4KIIIb are recruited to Golgi and lysosome membranes in NPC1 disease.
A
B

Diagram showing PtdIns4P metabolizing enzymes.
Representative Western blot for PI4KIIa and PI4KIIIb in control and U18-treated tsA201 cells. Protein levels were normalized to b-actin. Individual points (PI4KIIa:
n = 3; PI4KIIIb: n = 4) represent protein levels of each +U18 band normalized to control.
C
Left: Confocal images of control (left) and U18-treated (right) tsA201 cells expressing PI4KIIa-GFP. Bottom panels show an enlarged view of the probe centered on
a perinuclear region. Right: Quantification of perinuclear PI4KIIa intensity relative to the cytoplasm. Control: n = 12; U18: n = 14.
D
Same as (C) only PI4KIIIb. Control: n = 12; U18: n = 15.
E
Confocal images of control and U18-treated tsA201 cells fixed and stained for PI4KIIa (left), TGN46 (middle), and merge (right). Black rectangles show expanded
views of PI4KIIa and TGN46 regions.
F
Quantification of PI4KIIa signal in TGN46 regions (PI4KIIa TGN46). Control: n = 36; U18: n = 36.
G, H same as (E, F) only stained with PI4KIIIb. Control: n = 35; U18: n = 43.
I, J
same as (C, D) except using hippocampal neurons. (I) Control: n = 7; U18: n = 8. (J) Control: n = 6; U18: n = 6.
Data information: Data are all expressed as mean  SEM from individual cells, and all statistical analyses were conducted using unpaired t-test with **P < 0.01;
***P < 0.001; ****P < 0.0001.
Source data are available online for this figure.
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NPC1 function (Fig 1H–J). In line with the concept that PI4KIIa and
PI4KΙΙΙb are responsible for elevations in lysosomal PtdIns4P in
NPC1 disease, endogenous levels of both enzymes were significantly
elevated at LAMP1-positive membranes (Fig EV2E–H). These data
suggest a NPC1-dependent mechanism, conserved across multiple
cells types, for the recruitment of PI4KIIa and PI4KΙΙΙb to Golgi and
lysosome membranes.
DHHC3-dependent recruitment of PI4KIIa underlies NPC1dependent increases in Golgi PtdIns4P
Localization of PI4K isoforms can be influenced by a number of
factors including palmitoylation (Lu et al, 2012), phosphorylation
(Hausser et al, 2005), and protein interactions (Haynes et al, 2005;
Sasaki et al, 2012; Greninger et al, 2013; Chalupska et al, 2019).
For PI4KIIa, the lipid kinase activity, Golgi localization, and
membrane binding are dependent on the palmitoylation of a
cysteine-rich motif by DHHC3 and DHHC7 palmitoyl acyltransferases (Asp-His-His-Cys; DHHC; (Fig 4A)) (Lu et al, 2012). To confirm a central role for PI4KIIa in increasing subcellular PtdIns4P
levels following NPC1 loss of function, we first decided to knockdown PI4KIIa levels. To this end, we transfected Cas9-expressing
HEK293 cells for 48 h with sgPI4KIIa and a fluorescent transfection
marker. Western blot analysis revealed that total PI4KIIa protein
was reduced by ~ 75%, a reduction mirrored by immunofluorescence analysis from randomized regions of interest (Fig EV3A and
B). A targeted analysis of only those cells transfected with a fluorescent marker revealed a significantly larger, ~ 90% reduction in
immunofluorescence signal at Golgi regions (Fig EV3C). Based on
these analyses, all subsequent quantifications were performed on
cells positive for a transfection marker.

Candice Kutchukian et al

To test if reducing PI4KIIa protein levels affected NPC1dependent increases in PtdIns4P, we quantified the cellular distribution of P4M-YFP (Fig 4B and C). Comparing control, U18-treated,
and U18-treated PI4KΙΙa knockdown (“sgPI4KIIa”) cells revealed
that sgPI4KIIa significantly reduced steady-state and U18-dependent
increases in Golgi PtdIns4P (Fig 4B and C). To establish a role for
DHHC3 in recruiting PI4KΙΙa to the Golgi, we quantified the distribution of endogenous DHHC3 in control and NPC1I1061T patient fibroblasts. Analysis of immunofluorescent images revealed NPC1I1061T
fibroblasts had significantly elevated DHHC3 at Golgi regions
(Fig 4D and E). In contrast to endogenous DHHC3, the expression
of HA-DHHC7 was not significantly different between control and
NPC1I1061T patient cells (Fig EV3D) and was not further investigated. These data suggest that an increase in PI4KΙΙa palmitoylation
may underlie increases in PtdIns4P following loss of NPC1 function.
To test this hypothesis further, we overexpressed DHHC3 in control
fibroblasts to determine if simply increasing DHHC3 levels resulted
in changes to P4M and PI4KIIa at Golgi membranes. Quantitative
analyses revealed that overexpressing DHHC3 in control cells
resulted in an increase in both P4M (Fig 4F and G) and PI4KIIa
(Fig 4H and I), but not PI4KIIIb, at Golgi membranes to a similar
range as NPC1 cells. Thus, transiently overexpressing DHHC3
increases Golgi PtdIns4P to a similar level as NPC loss of function
cells. To further test a role for DHHC3 in recruiting PI4KΙΙa to Golgi
membranes, we knocked down DHHC3 by ~ 90% (“sgDHHC3”;
Fig EV3E) using CRISPR-Cas9 editing and found that reducing
DHHC3 levels in NPC1 loss of function cells normalized PtdIns4P
back into a control range (Fig 4J; analysis Fig 4C). To rule out
off-target effects of CRISPR editing or alterations in Golgi integrity
due to DHHC3 knockdown, we expressed a dominant-negative
DHHC3C157S plasmid (DN-DHHC3 (Lu et al, 2012)), that lacks the

Figure 4. NPC1 loss of function increases DHHC3-mediated PI4KIIa recruitment and PtdIns4P on Golgi and lysosome membranes.
A
B

Diagram illustrating the Golgi recruitment mechanisms of PI4KIIa.
Confocal images of wild-type and PI4KIIa-depleted (sgPI4K2A) HEK293-CAS9 cells expressing P4M-YFP, treated with or without U18. Bottom panels show enlarged
views of PtdIns4P in a Golgi region.
C Quantitative analyses of P4M-YFP mean fluorescence intensity distributed in Golgi normalized to the cytoplasm under different conditions. Control: n = 19; U18:
n = 13, sgPI4K2A: n = 19; sgPI4K2A+U18: n = 17; sgDHHC3: n = 11; sgDHHC3+U18: n = 11. * represents a significant difference (P < 0.05) between control and other
non-U18 treated groups; # represents a significant difference (P < 0.05) between U18-treated and other U18-treated sgRNA groups.
D Confocal images of control (top) and NPC1I1061T (bottom) patient fibroblasts immunolabeled for DHHC3 and Giantin. Insets show enlarged views of DHHC3 and
Giatin regions.
E Analysis of anti-DHHC3 mean fluorescence intensity in a Golgi region relative to cytoplasm. Control: n = 19; NPC1I1061T: n = 17.
F Confocal images of control (1st column) and NPC1I1061T fibroblasts (2nd column) expressing mCherry-P4M or control fibroblasts expressing P4M-mCherry and GFPDHHC3 (3rd column).
G Quantification of Golgi mCherry-P4M. Control: n = 11; NPC1I1061T: n = 14; control+DHHC3: n = 12.
H Control or GFP-DHHC3 expressing tsA201 cells fixed and stained for PI4KIIa or PI4KIIIb. Bottom panels show enlarged views of DHHC3, PI4KIIa, or PI4KIIIb at Golgi
regions.
I Quantification of PI4KIIa (left; control: n = 42, DHHC3: n = 24), or PI4KIIIb (right; control: n = 39, DHHC3: n = 26) intensity relative to cytoplasm.
J Top: HEK293-CAS9 cells expressing P4M and either vehicle control, sgDHHC3, U18, and U18 with sgDHHC3. Bottom: expanded views of P4M in the black dashed
rectangles.
K Control (left) and NPC1I1061T (right) patient fibroblasts expressing P4M-YFP (top row) or P4M-YFP and DHHC3C157S (DN-DHHC3; bottom row). Inset panels show
enlarged views of P4M-YFP distribution at Golgi.
L Quantification of P4M-YFP signal in the Golgi region relative to cytoplasm. NPC1I1061T: n = 20; NPC1I1061T + DN-DHHC3: n = 14.
M Confocal images of control (top row), NPC1I1061T (middle row), and NPC1I1061T treated with sgDHHC3 (bottom row) patient cells expressing P4M, LAMP1, and CAS9.
Insets are zoomed regions from LAMP1-positive areas.
N Quantification of P4M changes at endomembranes. Control: n = 149, U18: n = 251, sgPI4KIIa +U18: n = 131, sgDHHC3+U18: n = 271. Each n represents a single
enodolysosome.
Data information: All the data are expressed as mean  SEM from individual cells with the exception of (N) which represents values from individual subcellular
structures. Statistical analyses include two-way ANVOA (C, N), one-way ANVOA (G), unpaired t-test (E, I), or Mann–Whitney test (L). *P < 0.05; **P < 0.01; ****P < 0.0001.
Source data are available online for this figure.
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ability to palmitoylate PI4KΙΙa in TGN membranes (Lu et al, 2012),
and analyzed P4M and PI4KΙΙa distribution in control and
NPC1I1061T cells. Similar to DHHC3 knockdown, expression of DNDHHC3 in NPC1I1061T fibroblasts significantly reduced Golgi P4M
(Fig 4K and L) and PI4KΙΙa (Fig EV3F) back to control levels. Thus,
DHHC3-dependent recruitment of PI4KΙΙa appears to be part of the
mechanism that increases Golgi PtdIns4P in NPC1 disease.
Ordinarily, PI4KΙΙa is fully palmitoylated and behaves almost
entirely as an integral membrane protein (Barylko et al, 2009).
Thus, the increase in PI4KΙΙa observed in NPC1 fibroblasts, or
control cells overexpressing DHHC3, likely occurs due to a parallel
reduction in PI4KΙΙa from a different membrane compartment(s). To
begin testing this hypothesis, we fixed and stained control and

ª 2021 The Authors

NPC1I1061T patient fibroblasts for endogenous PI4KΙΙa and markers
of early endosomes (EEA1) and late endosomes (RAB7). Quantification of the subcellular localization between PI4KΙΙa and RAB7
revealed no clear differences between control and NPC1I1061T cells,
with a slightly reduced area of overall lap between signals (Fig EV4A–
C). Contrary to this modest finding, analysis of PI4KΙΙa and EEA1
determined a 50% reduction in both the area of overlap and the intensity of signal from NPC1I1061T cells relative to control (Fig EV4D–F).
Therefore, at least one subcellular compartment loses a significant
amount of PI4KΙΙa following loss of NPC1 function, that we suggest is
recruited to Golgi via DHHC3. Future experiments are needed to fully
dissect the molecular mechanism(s) underlying loss of PI4KΙΙa from
early endosomes and subsequent increase at TGN membranes.
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Finally, the increased localization of endogenous PI4KΙΙa to
LAMP1-positive structures in NPC1 cells (Fig EV2E and F) prompted
us to ask if DHHC3 localization was also increased at these
membranes. To address this question, we fixed control and
NPC1I1061T patient cells and quantified the distribution of DHHC3
on LAMP1-positive membranes. Similar to Golgi membranes, the
intensity of DHHC3 was significantly increased on lysosomes from
NPC1I1061T cells relative to control (Fig EV4G–I). To confirm a functional role for DHHC3 in regulating increases in lysosomal PtdIns4P
in NPC1 disease, we treated HEK293-Cas9 cells with sgDHHC3 and
compared the distribution of P4M relative to control cells. Consistent with DHHC3-dependent palmitoylation of PI4KΙΙa increasing
PtdIns4P on lysosomal membranes in NPC1 disease, knockdown of
lysosomal DHHC3 (Fig EV4J) in NPC1I1061T cells or HEK293-Cas9
cells normalized lysosomal P4M signals back to control levels
(Fig 4M and N).
Collectively, these data provide evidence that loss of NPC1 function initiates a signaling cascade that results in the recruitment of
PI4KΙΙa to Golgi and lysosome membranes, via DHHC3-dependent
palmitoylation, to increase PtdIns4P levels.
ACBD3-mediated recruitment of PI4KIIIb to Golgi and lysosomes
increases PtdIns4P levels in NPC1 disease
Having established a role for DHHC3-PI4KIIa increasing Golgi and
lysosome PtdIns4P levels in NPC1 disease, we next investigated the
mechanism underlying increased recruitment and/or activity of
PI4KΙΙΙb to Golgi and endolysosomal membranes following NPC1
loss of function. To begin, we asked if PKD-mediated phosphorylation of PI4KΙΙΙb underlies the U18-dependent increase in Golgi
PtdIns4P levels. PKD has a number of Golgi substrates, with its
recruitment linked to the stimulation of PI4KΙΙΙb lipid kinase activity
(Hausser et al, 2005) and OSBP localization (Nhek et al, 2010).
Despite strong rationale for its potential involvement, inhibition of
PKD activity failed to abrogate the U18-dependent increase in Golgi
PtdIns4P levels (Appendix Fig S5A and B).
PI4KΙΙΙb is a soluble lipid kinase that can interact with a number
of different proteins, including the multi-functional adaptor protein,
Acyl-CoA-binding domain-containing 3 (ACBD3; Fig 5A) (Sasaki
et al, 2012; Greninger et al, 2013; Chalupska et al, 2019). Therefore,
we tested if ACBD3 is involved in increasing PI4KΙΙΙb levels at Golgi
and endolysosome membranes. To begin, we quantified ACBD3
protein levels from control and NPC1I1061T patient cells via Western
blot and found cellular ACBD3 protein levels were significantly
increased in NPC1 disease cells (Fig 5B). Subsequent immunofluorescence analyses of ACBD3 revealed a general pattern consistent
with its reported localization at Golgi (Greninger et al, 2012; Sasaki
et al, 2012) and lysosome membranes (White et al, 2016) (Fig 5C),
with NPC1I1061T patient cells having significantly elevated levels of
ACBD3 at Golgi (Fig 5C and D) and endolysosomal regions
compared to control (Appendix Fig S5C and D). To test whether
increasing ACBD3 expression in control cells alters PtdIns4P and
PI4KIIIb to similar levels as NPC1 loss-of-function cells, we overexpressed GFP-ACBD3 and quantified Golgi P4M, PI4KIIa, and
PI4KIIIb. Consistent with a role for ACBD3 in mediating the
increases in PtdIns4P observed in NPC1 loss-of-function cells, overexpressing GFP-ACBD3 in control cells increased P4M (Fig 5E and
F) and PI4KIIIb (Fig 5G and H), but not PI4KIIa, at Golgi
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membranes. Therefore, like DHHC3, increasing ACBD3 expression
in control cells increases P4M and PI4KIIIb to similar levels as NPC1
loss-of-function cells. To further probe the hypothesis that loss of
NPC1 function drives ACBD3-dependent recruitment of PI4KΙΙΙb to
elevate Golgi and endolysosome PtdIns4P levels, we knocked down
ACBD3 (“sgACBD3”) and quantified Golgi and lysosomal PtdIns4P
levels. As before, treating HEK293-Cas9 cells expressing P4M-YFP
with U18 increased Golgi and lysosome PtdIns4P levels (Fig 5I and
J). Knocking down PI4KIIIb (“sgPI4KIIIb”; ~ 90% Fig EV3C) or
ACBD3 (“sgACBD3”; ~ 65% Fig EV3A and Appendix Fig S5E and F)
resulted not only in reduced steady-state PtdIns4P levels, but also
significantly reduced U18-mediated elevations in Golgi and lysosomal PtdIns4P (Fig 5I and J; Appendix Fig S5G). Interestingly, Golgi
PtdIns4P was refractory to U18-treatment when PI4KIIa and PI4KIIIb
were both knocked down (Fig 5J). We take this to mean that both
PI4K enzymes not only regulate basal Golgi PtdIns4P levels, but also
play important roles in mediating increases in Golgi PtdIns4P following loss of NPC function. While the underlying molecular elements of
this signaling pathway may be more complex, we believe that collectively our data present a model where NPC1-dependent increases in
ACBD3 protein levels at Golgi and lysosome membranes enhance
recruitment of PI4KIIIb to increase PtdIns4P synthesis.
Knocking down ACBD3 in NPC1I1061T patient cells rescues cellular
PtdIns4P phenotypes and prevents recruitment of mTORC1
A major cellular consequence of disease mutations in NPC1 is OSBPmediated accumulation of cholesterol on the cytoplasmic leaflet of
lysosome membrane which drives the recruitment of the master
regulator of growth signaling, mTORC1, resulting in aberrant growth
signaling (Lim et al, 2019). Under this model proposed by the Zoncu
group, a key factor initiating OSBP-mediated cholesterol transfer and
mTORC1 recruitment is the presence of lysosomal PtdIns4P which
binds to OSBP’s PH domain to tether ER-lysosome MCS. To date,
there are no reports identifying the phosphoinositide metabolism
elements required for cholesterol-dependent mTORC1 recruitment in
NPC1 disease. With this in mind, we transfected patient cells with
Cas9- and sgRNAs-directed against ACBD3, PI4KΙΙa, or PI4KΙΙΙb,
while simultaneously monitoring cellular PtdIns4P levels with the
P4M biosensor. In NPC1I1061T patient cells, individual knockdown of
either PI4KΙΙa or PI4KΙΙΙb significantly reduced both Golgi and lysosomal PtdIns4P levels (Fig 6A and B). It should be noted that sgPI4KIIIb was more efficient at reducing Golgi PtdIns4P than sgPI4KIIa in
NPC1I1061T cells, suggesting a more prevalent role in maintaining
Golgi PtdIns4P. This concept is further supported by immunofluorescence data that demonstrated a larger fold change in ACBD3 levels
(Appendix Fig S5C and D), compared to DHHC3 (Fig EV4G–I), at
lysosome membranes of NPC1I1061T cells relative to control.
To test if ACBD3 is necessary for increased lysosomal PtdIns4P
generation in NPC1 disease, we transfected sgACBD3 into
NPC1I1061T patient cells along with Cas9 and P4M-YFP. Similar, to
HEK293-Cas9 cells treated with U18 (Fig 5I and J), transfecting
sgACBD3 into NPC1I1061T rescued PtdIns4P at Golgi regions levels
back to control ranges and significantly reduced endolysosomal
PtdIns4P levels (Fig 6A and B). To test if increases in lysosomal
PtdIns4P production drives mTORC1 recruitment under NPC disease
conditions, we transfected Cas9 and sgACBD3 into NPC1I1061T
patient cells and fixed and stained for endogenous mTORC1. Similar
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Figure 5. ACBD3-mediated PI4KIIIb recruitment contributes to increased PtdIns4P levels at Golgi membranes following loss of NPC1 function.
A Diagram illustrating the Golgi recruitment mechanisms of PI4KIIIb.
B Representative Western blot for ACBD3 in control and NPC1I1061T patient fibroblasts. Protein levels were normalized to b-actin. Control: n = 26; NPC1I1061T: n = 27. A
paired t-test was used for the statistical analysis with *P < 0.05.
C Confocal images of control and NPC1I1061T patient fibroblasts immunolabeled for ACBD3. Black and orange squares show expanded views of anti-ACBD3 in Golgi and
endomembrane compartments, respectively.
D Analyses of ACBD3 intensity distributed in Golgi (left graph; Control: n = 9; NPC1I1061T: n = 9) or in endomembranes (right graph; Control: n = 1,360; NPC1I1061T:
n = 1,645 from 15 cells), normalized to the cytoplasm.
E Confocal images of control (1st column) and NPC1I1061T fibroblasts (2nd column) expressing mCherry-P4M or control fibroblasts expressing P4M-mCherry and GFPACBD3 (3rd and 4th columns).
F Quantification of Golgi mCherry-P4M intensity relative to cytoplasm. Control: n = 11; NPC1I1061T: n = 14; Control + ACBD3: n = 12.
G Confocal micrographs from control or GFP-ACBD3 expressing tsA201 cells fixed and stained for PI4KIIa or PI4KIIIb. Bottom panels show enlarged views of ACBD3,
PI4KIIa, or PI4KIIIb at Golgi regions.
H Quantification of PI4KIIa (left; control: n = 42; ACBD3: n = 28), or PI4KIIIb (right; control: n = 39; ACBD3: n = 20) intensity relative to cytoplasm.
I Confocal images of control and sgACBD3 HEK293-CAS9 cells expressing P4M-YFP, treated with or without U18. Bottom panels show enlarged views of PtdIns4P in
Golgi and in endomembrane compartments.
J Quantitative analyses of P4M-YFP mean fluorescence intensity at Golgi (left graph) or endomembranes (right graph) normalized to the cytoplasm. * represents a
significant difference (P < 0.05) between control and other non-U18 treated groups; # represents a significant difference (P < 0.05) between U18-treated and other
U18-treated sgRNA groups. For left graph; Control: n = 19; U18: n = 13; sgPI4KIIIb: n = 12; sgPI4KIIIb + U18: n = 11; sgPI4KIIa + sgPI4KIIIb: n = 12;
sgPI4KIIa + sgPI4KIIIb + U18: n = 12; sgACBD3: n = 15; sgACBD3+U18: n = 16. For right graph; control: n = 149; U18: n = 251; sgACBD3: n = 138; sgACBD3+U18:
n = 190. Please note that “control” and “U18” datasets in Fig 5J are identical to those in Fig 4C. Data for all CRISPR experiments were collected on the same days.
Data information: All the data are expressed as mean  SEM from individual cells with the exception of (D, right) and (J, right) which represents values from individual
subcellular structures, n = 10 cells and n = 13 cells, respectively. Statistical analyses include unpaired t-test (D left graph, H left graph), Mann–Whitney test (D right
graph, H right graph), or one-way ANOVA (F), *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. As determined by a Grubbs’ test, with an alpha value of 0.05 (see
methods), significant outliers were excluded from (J, right).
Source data are available online for this figure.
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to previous reports (Lim et al, 2019), NPC1I1061T disease mutations
result in increased steady-state accumulation of mTORC1 at lysosome membranes (Fig 6C). Knocking down ACBD3 in NPC1I1061T
cells significantly reduced lysosomal mTORC1 recruitment back into
a similar range as control cells (Fig 6C and D). Future experiments
are required to carefully dissect the downstream consequences of
decreased mTORC1 recruitment to lysosomal membranes following
reductions in PtdIns4P levels. These data underscore the importance
of lysosomal PtdIns4P metabolism for mTORC1 recruitment and
present PI4KΙΙΙb and ACBD3 as key regulators of cellular growth
signaling.

NPC1-dependent alterations in PI4K distribution are mediated
via the SREBP pathway
The data presented thus far provide evidence linking loss of NPC1
function to the DHHC3- and ACBD3-mediated recruitment of PI4K
enzymes to the TGN. The question remains, what is upstream of
these recruiting factors that mechanistically links loss of NPC1 activity to recruitment of PI4K enzymes and increases in Golgi PtdIns4P?
The major role of NPC1 is to facilitate the egress of cholesterol from
luminal to cytoplasmic leaflets of the lysosomal membrane bilayer.
Transported lysosomal cholesterol then serves as a signaling
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Figure 6. PtdIns4P produced by PI4KIIIb regulates mTORC1 recruitment to endomembrane compartments.
A Confocal images of control, NPC1I1061T and ACBD3-deleted NPC1I1061T patient fibroblasts expressing P4M-YFP. Black and orange squares show expanded views of
PtdIns4P in Golgi and endo/lysosomal compartments, respectively.
B Top graph: analysis of Golgi P4M-YFP intensity normalized to the cytoplasm in control and NPC1I1061T patient fibroblasts and NPC1I1061T fibroblasts lacking either
ACBD3 (“sgACBD3”), PI4KIIa (“sgPI4KIIa”) or PI4KIIIb (“sgPI4KIIIb”). Control: n = 9; NPC1I1061T: n = 12; NPC1I1061T + sgACBD3: n = 9; NPC1I1061T + sgPI4KIIa: n = 5;
NPC1I1061T + sgPI4KIIIb: n = 8. Bottom graph: analysis of P4M-YFP intensity in endomembrane compartments normalized to the cytoplasm in NPC1I1061T patient
fibroblasts. NPC1I1061T: n = 406; NPC1I1061T + sgACBD3: n = 172.
C Confocal images of control, NPC1I1061T and ACBD3-deleted NPC1I1061T patient fibroblasts immunolabeled with mTORC1 antibody. Bottom images show expanded
views of mTORC1 immunolabeling in the regions indicated by the dashed squares in the main images. White dashed lines represent the outline of each cell.
D Quantification of mTORC1 mean integrated density normalized by cell area in control, NPC1I1061T and ACBD3-deleted NPC1I1061T patient fibroblasts. Control: n = 15;
NPC1I1061T: n = 14; NPC1I1061T+sgACBD3: n = 11.
Data information: All the data are expressed as mean  SEM from individual cells with the exception of (B, bottom) which represents values from individual subcellular
structures. Statistical analyses include one-way ANVOA (B, top), Mann–Whitney test (B, bottom), and one-way ANOVA (D). *P < 0.05; **P < 0.01; ****P < 0.0001.
Source data are available online for this figure.
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molecule (Castellano et al, 2017; Lim et al, 2019) that can be indirectly transported to the plasma membrane (Infante & Radhakrishnan, 2017) or directly transferred to the ER at ER-lysosome MCS
(Rocha et al, 2009; Vihervaara et al, 2011). Levels of ER cholesterol
are precisely monitored by a family of transcription factors called
Sterol Regulator Element Binding proteins (SREBPs). Under conditions of reduced ER cholesterol levels, SREBPs are proteolytically
cleaved and subsequently translocate to the nucleus where they
upregulate the synthesis of many proteins (Brown & Goldstein,
1997; Rome et al, 2008). The general findings that de novo cholesterol synthesis, LDL uptake, and increased SREBP activity in
NPC1I1061T patient cells have been established (Pentchev et al, 1985;
Liscum & Faust, 1987; Frolov et al, 2003), therefore, we wanted to
test the hypothesis that SREBP activation was upstream of PI4K
recruitment to the Golgi.
To begin, we wanted to determine if SREBP impacts the transcription of DHHC3, ACBD3, PI4KΙΙa, and PI4KΙΙΙb. qPCR analysis of
mRNA levels revealed that DHHC3 and ACBD3 levels were elevated
in NPC1I1061T cells relative to control (Fig 7A), whereas PI4K levels
were unchanged. Treating NPC1I1061T cells overnight with the specific SREBP site 1 protease inhibitor, PF-429242 (PF), normalized transcript levels back into control ranges. These data are in line with
previously published microarray analysis detailing that ACBD3 is a
target gene for SREBP (Rome et al, 2008) and suggest that SREBP
may be responsible for the enhanced recruitment of PI4K enzymes to
the Golgi following loss of NPC1 function. To test this idea, we overexpressed fluorescently tagged PI4Ks in tsA201 cells and monitored
their distribution under conditions of altered NPC1 or SREBP function. Quantitative analysis of PI4KΙΙa distribution in cells treated
concurrently with U18 and PF-429242 revealed identical levels of
PI4KΙΙa at Golgi regions compared to vehicle-treated control cells
(Fig 7B and C). Similar analysis performed on GFP-PI4KΙΙΙb expressing cells revealed that PI4KΙΙΙb recruitment to Golgi membrane was
also refractory to U18 when treated concurrently with PF-429242
(Fig 7D and E). Parallel experiments investigating PtdIns4P metabolism revealed that U18-mediated increases in P4M intensity were
also sensitive to SREBP pathway inhibition (Fig 7F and G).
To provide further evidence for SREBP’s role in facilitating PI4K
recruitment, we generated two additional datasets using overexpressed SREBP and cells lacking functional SREBP. Overexpressing
SREBP increases the fractional amount of active, nuclear-localized
SREBP and as such provides a way to activate SREBP, independently of NPC1. Similar to U18-treated or NPC1 disease mutations,
cells overexpressing SREBP also had significantly elevated PI4KΙΙa
and PI4KΙΙΙb at Golgi regions (Appendix Fig S6A–D). To further

support a role for SREBP in mediating PI4K recruitment, we
analyzed the distribution of P4M in control cells relative to SCAP/
cells, that are unable to escort SREBP to the Golgi for processing to
its “active” nuclear form (Rawson et al, 1999). Consistent with
SREBPs involvement in mediating increases in Golgi and endomembrane PtdIns4P levels, P4M distribution in SCAP/ cells was similar to control (Fig 7H and I and Appendix Fig S6E and F). It should
also be noted that the distribution of SAC1 at the Golgi mirrored
changes in Golgi PtdIns4P levels (Appendix Fig S7), likely ensuring
the faithful maintenance of a steep PtdIns4P gradient for cholesterol
transport. These independent datasets provide preliminary evidence
that activation of SREBP maybe upstream of recruitment of PI4KΙΙa
and PI4KΙΙΙb to Golgi and endolysosomal regions.
NPC1-mediated elevations in Golgi PtdIns4P increase Golgi to
PM trafficking
We have identified a novel signaling axis that links NPC1-mediated
cholesterol efflux to tuning of molecular contents of ER-TGN MCS. A
key remaining question is with regard to the functional consequence
of aberrant Golgi PtdIns4P in NPC disease. Golgi PtdIns4P plays a
crucial role in the spatial and temporal recruitment of adaptor proteins
to facilitate anterograde trafficking of cargo proteins destined for endosomes and the PM. While acute depletion of PtdIns4P prevents the exit
of cargo from the Golgi destined for the PM, increased Golgi PtdIns4P
leads to a malignant secretory phenotype in cancer (reviewed Waugh
(2019)). To dissect a role for NPC1 in regulating secretory traffic, we
first measured the distribution of cation-independent mannose 6phosphate receptors (CI-MPR). These receptors are dynamically trafficked between the TGN and endosomes, as well as the PM and as
such give a broad overview of secretory trafficking patterns (Dong
et al, 2016). Control and NPC1II061T patient cells were incubated with
anti-CI-MPR (binds the extracellular region of CI-MPR at the PM) for
1 h, and the intracellular distribution of CI-M6PR antibody was
detected by immunofluorescence. Quantitative analysis of the resulting confocal micrographs revealed that the CI-M6PR antibody was
internalized with the receptor and accumulated at Giantin-positive
Golgi membranes in control patient cells (Fig 8A, left middle row), as
well as other non-giantin-positive internal membranes that likely
correspond to endosomes (Fig 8A, left bottom row; Fig EV5A and B).
In contrast, NPC1II061T patient cells had a significantly higher accumulation of CI-MPR fluorescence at the Golgi (Fig 8A, right panel),
coupled with decreased levels of fluorescence at peripheral vesicles
(Fig 8A, right panel; Fig 8B for analysis). Thus, trafficking patterns
are altered following loss of NPC1 function.

Figure 7. SREBP inhibition alleviates NPC1-dependent increase of PI4KIIa, PI4KIIIB, and PtdIns4P levels at Golgi membranes.
qPCR analysis from control (black bars), NPC1I1061T (pink), and NPC1I1061T patient cells treated overnight with the SREBP inhibitor, PF-429242 (1 lM; blue bars).
Error bars represent SEM from 6 technical and 2 biological replicates.
B
Confocal images of tsA201 cells expressing PI4KIIa-GFP. Cells were treated with either vehicle (control), U18, or U18 and PF for 24 h prior imaging. Bottom panels
show an enlarged view of the enzyme in a perinuclear area.
C
Quantification of PI4KIIa-GFP mean fluorescence intensity in Golgi normalized to the cytoplasm. Control: n = 12; U18: n = 14; U18+PF: n = 12.
D, E Same as (B, C) but in tsA-201 cells transfected with PI4KIIIb-GFP. Control: n = 18, U18: n = 22, U18+PF: n = 23.
F, G Same as (B, C) but in tsA-201 cells transfected with P4M-YFP. Control: n = 39, U18: n = 42, U18+PF: n = 32.
H, I Same as (F, G) but in wild-type and SCAP/ CHO cells. Control: n = 12, U18: n = 11, SCAP/ +U18: n = 10.
A

Data information: All the data are expressed as mean  SEM from individual cells and all statistical analyses were conducted using a two-way ANOVA (A) or one-way
ANVOA (C, E, G, I). *P < 0.05; **P < 0.01 and ****P < 0.0001.
Source data are available online for this figure.
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To more specifically test if NPC1 loss of function can alter Golgi
trafficking/sorting, we quantified the cellular distribution of the
small GTPase ARF1. ARF1 has a well-established role in the assembly and budding of COPI vesicles at the Golgi, where its active form
recruits coatomer for the formation of COPI-coated vesicles (Serafini
et al, 1991; Palmer et al, 1993). With this in mind, analysis of
expression patterns of ARF1-GFP revealed significantly greater accumulation at Golgi regions of NPC1I1061T cells relative to control
(Fig 8C and D). In addition, we also noticed more ARF1-positive
tubular structures protruding from the Golgi region (Fig 8C, black
arrows). These ARF1 tubules have previously been suggested to
represent the major membrane flow out of the Golgi, with approximately one-third required to maintain plasma membrane growth
(Bottanelli et al, 2017). These data, combined with increases in
Golgi PtdIns4P (Fig 1), indicate that Golgi secretions may be accelerated following loss of NPC1 function.
To analyze and quantify transport characteristics in cells lacking
functional NPC1, we utilized the retention using hooks (RUSH)
assay (Boncompain et al, 2012). The RUSH system is based on the
reversible interaction of a “hook” protein fused to streptavidin (Str)
and stably anchored in a donor compartment with a reporter protein
of interest fused to streptavidin-binding peptide (SBP). The addition
of Biotin facilitates the release of the reporter from the organellelocalized hook and triggers the secretion of cargo. Fusion of a fluorescent protein to the reporter protein allows for the tracking and
quantification of secretion rates between different organelles. Using
the RUSH system, we retained cargo (tumor necrosis factor a (TNFa);
TNF-SBP-mCherry), destined for the PM, in the ER (Str-KDEL) and
analyzed the transport kinetics following the addition of Biotin (Fig 8E
and F). Experiments performed at 37°C showed that TNFa-SBPmCherry was initially retained in the ER (t = 0 s) through the interactions with Str-KDEL. Addition of Biotin facilitated the release of the
reporter and its subsequent trafficking to Golgi apparatus within
15 min (Fig 8E and F; “control”, black trace), before reaching the PM
within ~ 25 min. Time series analysis of Golgi regions of interest from
control cells revealed that the rate of TNFa-SBP-mCherry

accumulation had a time constant of approximately 454 s (Fig 8G,
bottom, Tauarrive Golgi), an interval between 50% increase in intensity
and 50% decrease in intensity (50:50 duration) of 1,200 s, and a rate
of anterograde secretion to proximal membranes of approximately
1,548 s (Tauleave). In contrast, cells treated overnight with U18, to
inhibit NPC1 function, had significantly altered trafficking kinetics
with the average time constant of Golgi accumulation (U18:
Tauarrive = 205 s), 50:50 duration (U18: 780 s), and secretion rate
from the Golgi (U18: Tauleave 294 s) all significantly faster (Fig 8E–G;
red images, lines, and histograms). In addition, we analyzed TNFaSBP-mCherry intensity from ER regions of interest and determined
that the overall rate of secretion from the ER is similar between control
and U18-treatment, with a key difference being that cargo is released
sooner from U18-treated cells (Fig EV5C).
To understand how NPC1-dependent changes in trafficking may
influence anterograde secretion toward the PM, we conducted similar experiments using TIRF microscopy (Fig 8H and I). In resting
control cells, TNFa-SBP-mCherry was visualized within the TIRF
footprint as discrete puncta, likely representing regions of close
opposition between the ER and PM. Upon the addition of Biotin,
there was an initial loss of intensity within the TIRF evanescent field
which represents the cargo exiting the ER and trafficking to the
Golgi (Fig 8H, black “control”). Within as little as 1,000 s, individual puncta, which we suggest are secretory vesicles fusing with the
PM, reappeared within the TIRF field of view and were accompanied with a concurrent increase in intensity within a ROI encompassing the entire TIRF footprint. Analysis from control cells
revealed the TIRF footprint intensity increased 2.5-fold with an average time constant 863 s (Fig 8H–J). Comparing control to U18treated cells revealed that secretion of TNFa-SBP-mCherry from the
ER to the PM was significantly faster (U18: Tauarrive = 404 s), with
more cargo trafficked to the PM per unit time (5.2-fold change;
Fig 8I and J; red “+U18”). Similar U18-dependent increases in trafficking kinetics were observed with a VSVG plasmid that was
released directly from the Golgi (Fig EV5D). Next, we tested a role
for DHHC3 and ACBD3 in mediating U18-dependent increases in

Figure 8. SREBP inhibition alleviates vesicular trafficking defects in NPC1 disease.
A
B
C
D
E
F
G
H
I
J

Confocal images of control and NPC1I1061T patient fibroblasts immunolabeled for Giantin and CI-M6PR. Insets show expanded views of each immunolabeling in the
Golgi region (upper insets) or centered on endomembranes (bottom inset, merged signals). Dashed gray and white lines represent the outline of each cell.
Analysis of the mean area of M6P and Giantin colocalizing puncta (top graph; Control: n = 23; NPC1I1061T: n = 18) and of their mean fluorescence intensity (bottom
graph; Control: n = 18; NPC1I1061T: n = 18) in control and NPC1I1061T patient fibroblasts.
Confocal images of control and NPC1I1061T patient fibroblasts expressing ARF1-GFP. Insets show enlarged views of ARF1 in the Golgi area. Tubular structures were
observed in NPC1I1061T patient fibroblasts as indicated by the black arrows.
Quantification of ARF1 fluorescence intensity in Golgi normalized to the cytoplasm in control and NPC1I1061T patient fibroblasts. Control: n = 10; NPC1I1061T: n = 11.
Live confocal images of control and U18-treated cells transfected with Str-KDEL_TNF-SBP-mCherry. Images are taken at the indicated time points after biotin
addition (at time 0 s) and the corresponding distribution of the TNF-SBP-mCherry within the cell is illustrated in the upper row.
Average time course of mean TNF-SBP-mCherry fluorescence intensity in Golgi normalized to the initial fluorescence value. Shaded area represents the SEM. Control:
n = 11; U18: n = 15.
Analysis of the time constants for TNF-SBP-mCherry to reach and to leave the Golgi (Tauarrive and Tauleave Golgi, respectively) and the full duration at half maximum
(50:50 Duration), calculated from the upper traces. Error bars represent SEM. Control: n = 10; U18: n = 13–15.
Same as (E) except images are TIRF footprints of tsA201 cells treated either with vehicle (control) or with U18.
Averaged time course of the mean plasma membrane fluorescence intensity normalized to the initial fluorescence value in tsA201 cells treated either with vehicle
(control), with U18 alone, or together with PF. Shaded area represents the SEM, n = 9.
Quantitative analysis of the time constants for TNF-SBP-mCherry to reach the plasma membrane (Tauarrive PM) and the maximal change in fluorescence intensity
relative to the initial fluorescence value (Intensity Change TIRF F/F0). Error bars represent SEM. Control: n = 6–9; U18: n = 8–9; U18+PF: n = 5–9.

Data information: All the data are expressed as mean  SEM from individual cells, and all statistical analyses were conducted using unpaired t-test with *P < 0.05,
**P < 0.01, ***P < 0.001 and ****P < 0.0001.
Source data are available online for this figure.
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Golgi secretion. To begin, we overexpressed DHHC3 and/or ACBD3
and found that while their individual expression increased trafficking rates to the PM, it was their dual expression that increased
trafficking rates to the same extent as U18 (Fig EV5E). Conversely,
knocking down either DHHC3 or ACBD3 abrogated U18-dependent
increases in TNFa-SBP-mCherry secretion (Fig EV5F). Finally, we
tested the involvement of the SREBP pathway in facilitating the
increases in trafficking observed with U18 treatment. Consistent
with its ability to regulate PI4K and PtdIns4P levels at the Golgi
(Fig 7), SREBP overexpression accelerated secretion (Fig EV5G),
while cells treated with a SREBP inhibitor were refractory to
changes by U18 (Fig 8I and J; blue line) with the rate of traffic to
the PM (PF: Tauarrive = 720 s) and overall amount (2.9-fold change)
of cargo delivered not statistically different from control. Collectively, these data support a role for NPC1 in tuning Golgi secretion
through SREBP-dependent control of Golgi PtdIns4P.

Discussion
We have identified a novel signaling axis that connects NPC1 cholesterol efflux to the regulation of Golgi and lysosomal PtdIns4P levels
(Appendix Fig S8). The molecular steps linking changes in the functional status of NPC1 to alterations in membrane PtdIns4P levels
appear to involve cholesterol-dependent transcriptional changes in the
recruitment machinery of PI4K metabolizing enzymes. Specifically,
we have discovered that loss of NPC1 function increases DHHC3 and
ACBD3 levels to enhance recruitment of PI4KΙΙa and PI4KΙΙΙb at Golgi
and lysosomes, leading to elevations in membrane PtdIns4P.
Crucially, we demonstrate this signaling node is conserved across
multiple cell types, including patient cells and mouse neurons harboring the most prevalent NPC disease mutation. The importance of this
signaling pathway in health and NPC disease is underscored by experiments demonstrating that loss of NPC1 function causes aberrant
increases in anterograde trafficking and recruitment of the master
growth regulator mTORC1 at the Golgi and lysosome membranes,
respectively. Thus, NPC1 is a crucial rheostat capable of tuning cellular growth and rate of delivery of proteins to cellular membranes.
At the core of our findings is the recruitment of PI4KΙΙa and PI4KΙΙΙb
to both Golgi and lysosome membranes following loss of NPC1 function. The presence of these PI4K enzymes at Golgi and lysosome
membranes has been independently reported by multiple groups
(Wong et al, 1997; Wei et al, 2002; Guo et al, 2003; Wang et al, 2003;
Waugh et al, 2003). For PI4KΙΙa, significant evidence suggests a key role
for palmitoylation-dependent recruitment to Golgi membranes by
palmitoyl acyltransferases, such as DHHC3/7 (Lu et al, 2012). Our
evidence for the involvement of DHHC3 in recruiting PI4KΙΙa to
increase Golgi PtdIns4P is (i) DHHC3 enrichment at Golgi membranes,
(ii) overexpression of DHHC3 increases PI4KIIa and PtdIns4P levels at
Golgi membranes, (iii) knockdown of DHHC3 reduces Golgi PtdIns4P
levels in NPC1 cells, and (iv) overexpression of a dominant-negative
protein that lacks the ability to palmitoylate PI4KΙΙa, reduces PI4KΙΙa
recruitment and elevations in PtdIns4P in NPC1 patient cells. Interestingly, we also find that knockdown of DHHC3 or PI4KΙΙa in NPC1deficient cells significantly reduces lysosomal PtdIns4P, an observation
consistent with its presence at lysosome membranes. This model is
supported by our own report of DHHC3 and PI4KΙΙa on lysosomes, and
independent reports of PI4KΙΙa (Lim et al, 2019), as well as other
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DHHC5 and DHHC20 palmitoyl acyltransferases (Liu et al, 2018; Lim
et al, 2019), on lysosome membranes and suggests DHHC-dependent
recruitment of PI4KΙΙa to lysosomes could be a mechanism for tuning
lysosomal PtdIns4P levels. As noted, under normal cellular conditions
PI4KΙΙa appears to be fully palmitoylated and essentially acts as an integral membrane protein. This means that NPC1-mediated increases in
Golgi or lysosome PI4KΙΙa likely occur as a consequence of reductions
in PI4KΙΙa at other subcellular compartments. Our data suggest loss of
PI4KΙΙa from early endosome compartments may provide the substrate
for DHHC3 to elevate levels at Golgi and lysosome membranes. Future
experiments are required to rigorously test this hypothesis.
In the case of PI4KΙΙΙb, our analysis details an important role for
ACBD3 in facilitating the increases in Golgi and lysosome PtdIns4P,
consistent with reports specifying interactions between the N-terminus
of PI4KΙΙΙb and ACBD3 (Sasaki et al, 2012; Klima et al, 2016). Despite
its crucial role in recruiting PI4KΙΙΙb to the Golgi, there are only a few
reports of it being localized to lysosome membranes (White et al, 2016;
Liu et al, 2018). Our super-resolution imaging analysis determined that
the cellular fraction of ACBD3 coincident with LAMP1 and PI4KΙΙΙb
levels are both significantly elevated at lysosome membranes following
loss of NPC1 function. Furthermore, we find that knockout of either
ACBD3 or PI4KΙΙΙb significantly reduces PtdIns4P levels across different
cells lacking NPC1 function. These data are consistent with a NPC1dependent mechanism that facilitates ACBD3-mediated recruitment of
PI4KΙΙΙb to lysosome membranes. It should be noted that we also see
an elevation in the abundance of ARF1 at Golgi membranes. This is
important because it has been proposed that ACBD3 controls the Golgi
recruitment of PI4KΙΙΙb, which in turn recruits c10orf76 to influence the
dynamics and localization of Arf1-GTP, to activate PI4KΙΙΙb (McPhail
et al, 2019). Thus, the observed increases in Golgi PI4KΙΙΙb and
PtdIns4P could be under the dual regulation of ACBD3 and ARF1 in
NPC1 disease. It should be noted that in our experiments we use overexpression and knockdown of proteins to test a role for ACBD3 and
DHHC3 in recruiting PI4K enzymes to Golgi and lysosomal membranes.
These approaches offer ways to dramatically increase or decrease
protein levels to test their involvement in facilitating increases in
PtdInsP levels following loss of NPC1 function. Future experiments,
that precisely titrate protein levels to the same magnitude as observed
in NPC1 loss of function cells, will be required to fully test whether
changes in recruitment of these proteins to Golgi or lysosome
membranes are necessary or sufficient for the observed changes in
PtdInsP levels, trafficking, and mTORC recruitment.
A key question remaining is the molecular timing of PtdIns4P
increases at Golgi and lysosome membranes following loss of NPC1
function. We offer three simple, and certainly not exhaustive
models. First, the simplest interpretation is that both enzymes are
concurrently recruited to each organelle membrane to elevate
PtdIns4P levels. This model is supported by the presence of recruitment machinery and enzymes at both organelles. An alternative
model involves PI4KIIa/ΙΙΙb synthesizing PtdIns4P only at Golgi
membranes, with exiting vesicles entering the endolysosomal pathway having excess PtdIns4P. If correct, the fraction of PI4KIIa/ΙΙΙb
we observe on lysosomes would merely be coincident with PtdIns4P
elevations and thus would likely not have local access to their
PtdIns substrate. In a final, sequential model, influenced by the
Balla group (Jovic et al, 2012), ACBD3-PI4KIIIb generates PtdIns4P
at the Golgi, to allow for efficient exit of cargo destined for lysosomes, while DHHC3-PI4KIIa generates PtdIns4P on late endosomes
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to enable efficient cargo transport to lysosomes. Here, the
compound elevations in PtdIns4P levels would sequentially increase
PtdIns4P levels across the endolysosomal pathway. Each of these
models offers several interesting avenues for future exploration.
An intriguing observation in the course of our studies is the fluidity of proteins within membrane-membrane contact sites (MCS).
While much research has characterized the identity of many of the
proteins within ER-TGN and ER-lysosome MCS, little is known about
the molecular choreography of these proteins and how exactly they
are modified during pathophysiological conditions. Here we show
that loss of NPC1 function leads to a functional reorganization of key
components of the cholesterol/PtdIns4P cycle and represents one of
the first reported examples of fine-tuning of these transfer portals in
disease. Our data reveal enhanced recruitment of OSBP, VAPA, and
SAC1 to ER-TGN MCS in cells harboring NPC1 disease mutations.
We suggest the molecular rearrangement of these MCS proteins
likely occurs downstream of PI4K-dependent generation of Golgi
PtdIns4P. In our model, increased Golgi or lysosome PtdIns4P levels
would recruit OSBP through binding of its PH domain to PtdIns4P,
while interactions with VAP would engage the ER. Increased tethering of OSBP at MCS would amplify PtdIns4P and cholesterol transport to ER and donor membranes, respectively. This leaves SAC1 the
crucial task of dephosphorylating transferred PtdIns4P to PtdIns on
ER membranes. This key step ensures the maintenance of the steep
PtdIns4P gradient and positions SAC1 is as key regulator of the OSBP
cycle. Key questions remain for the cholesterol/PtdIns4P cycle in
NPC1 disease, such as, (i) what effect does altered NPC1 and OSBP
function have on TGN cholesterol? (ii) What influence do cholesterol
levels at ER and TGN membranes have on cholesterol sensitive
proteins like PI4KIIa (Waugh et al, 2006) or membrane proteins like
VAPA and SAC1, that are well positioned to sense variations in
cholesterol levels (Wakana et al, 2021), and (iii) how are PI4KIIa
and IIIb spatially and temporally coupled at ER-TGN MCS to organize cholesterol and PtdIns4P transport?
In the context of NPC1 disease, as in other cancers/aging/neurological disorders (Condon & Sabatini, 2019), the recruitment of
mTORC1 to lysosome membranes would initiate aberrant growth
pathways leading to inhibition of essential autophagic clearing functions and buildup of toxic metabolites. In NPC disease, the sequence
of events leading to mTORC1 recruitment to lysosome membranes
begins with reduced cholesterol efflux across the lysosome
membrane leading to the initiation of the following pervasive signaling reaction: (i) increased PI4K-dependent production of PtdIns4P
(this manuscript), (ii) increased lysosomal PtdIns4P facilitates
increased engagement of OSBP at ER-lysosome MCS (Lim et al,
2019), leading to (iii) a steeper PtdIns4P gradient to drive cholesterol

transport from the ER to lysosome membrane (Mesmin et al, 2013;
Lim et al, 2019), thereby (iv) assisting in the recruitment of mTORC
(Castellano et al, 2017; Lim et al, 2019). It should be noted that
previous work, using similar cell lines, demonstrated that both
recruitment and downstream activity of mTORC1 are increased
following loss of NPC1 function (Castellano et al, 2017; Lim et al,
2019). We show that mTORC1 recruitment is altered following
knockdown of ACBD3, careful investigations are still required to
dissect the downstream consequences of PI4K-mediated mTOR activity. mTOR has also been demonstrated to contribute to SREBP activation, by controlling the nuclear entry of Lipin-1 (Peterson et al,
2011). Activated mTORC1 has been shown to phosphorylate lipin 1
to retain it in the cytoplasm, allowing nuclear SREBP binding to
target genes resulting in increased lipogenesis. In the context of our
data detailing a potential role for SREBP in enhancing the recruitment of PI4K enzymes, mTORC1 activation may remove an inhibitory brake on SREBP target genes, to increase lysosomal PtdIns4P
thereby strengthening and perpetuating mTORC1 recruitment.
It remains to be fully determined if NPC1-dependent increases in
Golgi membrane PtdIns4P levels represent a cellular signaling pathway that compensates for altered cholesterol homeostasis to
preserve cerebellar neuron integrity or destructively contributes to
the death of vulnerable Purkinje neurons (Praggastis et al, 2015).
Given that PI4K enzymes and PtdIns4P have been implicated across
a wide range of neuronal functions and pathologies, including
Gaucher disease (Jovic et al, 2012), spinocerebellar degeneration
(Simons et al, 2009), myelination (Alvarez-Prats et al, 2018), and
Schizophrenia (Jungerius et al, 2008; Houlihan et al, 2009), our
results suggest that the NPC1-dependent elevations in Golgi
PtdIns4P leading to enhanced anterograde Golgi trafficking will
likely be deleterious to neuronal fidelity. Lessons from cell biology
and cancer inform us of the importance of regulated PtdIns4Pdependent trafficking events at the Golgi (reviewed Waugh (2019))
and how their dysfunction leads to alterations in the PtdIns4P
protein interactome, a malignant secretory phenotype, and tumor
progression.
In conclusion, we propose that lysosomal NPC1-mediated cholesterol efflux modulates the SREBP-dependent recruitment of PI4K
enzymes to control the molecular organization of ER-TGN and ERlysosome membrane contact sites, thereby tuning mTORCdependent growth conditions and anterograde trafficking in health
and disease. Collectively, this information presents intriguing possibility that similar to cancer, targeting these enzymes, their chaperones, substrates, and/or products in neurodegenerative disease,
may offer therapeutic checkpoints for devising strategies to slow
neuronal death and hence disease progression.

Materials and Methods
Reagents and Tools table
Reagent or resource

Source

Identifier

Antibodies
Rabbit polyclonal PI4KIIa

Abcam

Cat# ab71824; RRID: AB_1269758

Rabbit polyclonal PI4KIIa

P. De Camilli, Yale University School of
Medicine, New Haven, CT

N/A

Mouse monoclonal PI4KIIa

Santa Cruz

Cat# sc-390026
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Reagents and Tools table (continued)
Reagent or resource

Source

Identifier

Rabbit polyclonal PI4KIIIb

Abcam

Cat# ab109418; RRID: AB_10861028

Mouse monoclonal PI4KIIIb

BD Biosciences

Cat# 611816; RRID: AB _399296

Sheep polyclonal TGN46

Bio-Rad

Cat# AHP500GT; RRID: AB_2203291

Mouse monoclonal TGN46

Novus

Cat# NBP1-49643; RRID: AB_10011762

Mouse monoclonal EEA1

BD Biosciences

Cat# 610456, RRID: AB_ 397829

Mouse monoclonal RAB7

Santa Cruz Biotechnology

Cat# sc-271608; RRID: AB_10649046

Mouse monoclonal b-actin

Thermo Fisher Scientific

Cat# MA1-91399, RRID: AB_2273656

Mouse monoclonal VAPA

J. Trimmer, UC Davis, Davis, CA

N/A

GAPDH

Proteintech

10494-1-AP

Rabbit polyclonal OSBP

Atlas antibodies

Cat# HPA039227; RRID: AB_2676401

Rabbit polyclonal DHHC3

Abcam

Cat# ab31837; RRID: AB_742236

Rabbit polyclonal SAC1

Atlas Antibodies

Cat# HPA069869; RRID: AB_2686216

Mouse monoclonal ACBD3

Santa Cruz Biotechnology

Cat# sc-101277; RRID: AB_2273355

Mouse monoclonal Giantin

Abcam

Cat# ab37266; RRID: AB_880195

Rabbit polyclonal Giantin

BioLegend

Cat# 924302; RRID: AB_2565451

Mouse monoclonal Lamp1

Abcam

Cat# ab25630; RRID: AB_470708

Rabbit polyclonal Lamp2

Invitrogen

Cat# PA1-655; RRID: AB_2134625

Rabbit monoclonal mTOR

Cell Signaling Technology

Cat# 2983S

Goat anti-Mouse, Alexa Fluor 647

Invitrogen

Cat# A-21236; RRID: AB_141725

Goat anti-Rabbit, Alexa Fluor 488

Invitrogen

Cat# A-11034; RRID: AB_2576217

Donkey anti-Sheep, Alexa Fluor 555

Invitrogen

Cat# A-21436; RRID: AB_2535857

Goat anti-Rabbit 680RD

LI-COR Biosciences

Cat# 926-68071; RRID: AB_10956166

Goat anti-Mouse 800CW

LI-COR Biosciences

Cat# 925-32210, RRID: AB_2687825

B27

Gibco

Cat#17504-044

Glutamax

Gibco

Cat#35050-061

Cytosine-D-arabinofuranoside

Millipore

Cat#251010

U18666A

Sigma-Aldrich

Cat#U3633

PF-429242

Tocris

Cat#3354

Lipofectamine 2000

Invitrogen

Cat#11668-027

Lipofectamine LTX

Invitrogen

Cat#15338-030

Lipofectamine RNAiMAX

Invitrogen

Cat#13778-030

Chemicals, peptides, and recombinant proteins

Paraformaldehyde

Electron Microscopy Sciences

Cat#15710

Glutaraldehyde

Sigma

Cat# G7651

Filipin

Sigma

Cat#F9765

SEA BLOCK Blocking Buffer

Thermo Scientific

Cat# 37527

Complete Mini protease inhibitor cocktail

Roche

Cat# 11836170001

PowerUp SYBR Green Master Mix

Thermo Fisher Scientific

Cat#A25742

Pierce BCA Protein Assay Kit

Thermo Fisher

Cat# 23225

AffinityScript QPCR Synthesis Kit

Agilent technologies

Cat#600559

RNeasy Plus Mini Kit

Qiagen

Cat#74134

Critical commercial assays

Experimental models: cell lines
Control patient-derived fibroblasts

Coriell Institute

Cat# GM05659

NPC1I1061T patient-derived fibroblasts

Coriell Institute

Cat# GM18453
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Reagents and Tools table (continued)
Reagent or resource

Source

Identifier

NPC1/ CHO cell line

Millard et al (2000)

N/A

HEK293 Cas9 cell line

ATCC

Cat# CRL-1573Cas9

HEK293 eGFP-Sac1

Zewe et al (2018)

N/A

tsA201 Cell Line

Sigma

Cat# 96121229

Experimental models: organisms/strains
E18 mouse embryos

JAX

Oligonucleotides
sgRNA targeting PI4K2A sequence: CCATTGACCGAGTGAAGTCC

Integrated DNA Technologies

N/A

sgRNA targeting PI4K3B sequence: CCACTCAACGACACTCCCGT

Integrated DNA Technologies

N/A

sgRNA targeting ACBD3 sequence: GAGCTTGACAAACTCCACCA

Integrated DNA Technologies

N/A

sgRNA targeting DHHC3 sequence:
CGGAATTGTGTTCAACCTGC

Integrated DNA Technologies

N/A

PrimeTime qPCR PI4KIIa Primers:

Integrated DNA Technologies

Hs.PT.58.733616

PrimeTime qPCR PI4KIIIb Primers:

Integrated DNA Technologies

Hs.PT.58.14990511

PrimeTime qPCR ACBD3 Primers

Integrated DNA Technologies

Hs.PT.58.26724987

PrimeTime qPCR DHHC3 Primers

Integrated DNA Technologies

Hs.PT.58.45384099

PrimeTime qPCR HPRT Primers

Integrated DNA Technologies

Hs.PT.58v.45621572

Kruse et al (2016)

N/A

Recombinant DNA
P4M-YFP
pGFP-P4M

Hammond et al (2014)

mCherry-P4M

Hammond et al (2014)

N/A

GFP-tagged PI4KΙΙa and PI4KΙΙΙb

Balla et al (2002)

N/A

GFP-DHHC3

This paper

N/A

GFP-ACBD3

This paper

N/A

HA-tagged DHHC3, DHHC3 (C157S), DHHC7, DHHC7 (C160S) and
GSD

Fukata et al (2004)

N/A

LAMP1-RFP

Addgene

Cat#1817

LAMP1-mGFP

Addgene

Cat#34831

LAMP1-CFP

Komatsu et al (2006)

N/A

SEC61b-mCherry

Dickson et al (2016)

N/A

OSH1-GFP

Szentpetery et al (2010)

N/A

2xFLAG-SREBP-1a

Addgene

Cat#26801

Str-Golgin84_VSVG-SBP-EGFP

Addgene

Cat#65305

pTGN38-CFP

Szentpetery et al (2010)

Str-KDEL_TNF-SBP-mCherry

Addgene

Cat#65279

ImageJ

NIH

https://imagej.nih.gov/ij/

Micro-manager

NIH

https://micro-manager.org

ZEN imaging software

Zeiss

RRID: SCR_013672

Software and algorithms

MassLynx software

Waters

RRID: SCR_014271

GraphPad Prism8

GraphPad

RRID:SCR_002798

Polyacrylamide Bis-Tris gel

Invitrogen

Cat# NW04120BOX

Polyvinylidene difluoride membrane

Life Technologies

Cat# LC2000

Other
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Methods and Protocols

Filipin staining and imaging
Cholesterol was stained according to a previously described procedure (Vivas et al, 2019). Cells were first fixed with 4%
paraformaldehyde and 0.1% glutaraldehyde in phosphate-buffered
saline (PBS) for 10 min at room temperature, before being incubated for 2 h at room temperature in PBS containing filipin at 3 mg/
ml. After 5 × 5 min washes in PBS, cells were imaged in PBS under
a Zeiss 880 AiryScan confocal microscope. Filipin fluorescence was
visualized using 405 nm excitation.

Cell culture
All the cell lines were incubated at 37°C and 5% CO2 and subcultured twice weekly. Patient fibroblasts from an apparently
healthy male (control) and a male with a homozygous mutation in
NPC1I1061T were purchased from Coriell Institute and were grown in
Eagle’s Minimum Essential Medium (MEM) supplemented with
2 mM L-glutamine, 10% FBS and 0.2% penicillin/streptomycin.
Control, NPC1/ (Millard et al, 2000), and SRD-13A CHO cells
(Rawson et al, 1999) (SCAP/) (kindly provided by D. Ory, Washington University, St. Louis, MO), HEK293 cells that stably express
Cas9 (HEK293-CAS9) were purchased from ATCC (CRL-1573Cas9).
tsA201 cells were cultured in DMEM-based proliferation medium
containing 10% FBS and 0.2% penicillin/streptomycin. HEK293
cells stably expressing eGFP11-Sac1 and eGFP11-Sec61b were kindly
provided by G. Hammond (Zewe et al, 2018) (University of Pittsburgh School of Medicine, Pittsburgh, PA) and were cultured in the
same way as tsA201 cells. COS7 cells were a kind gift from Dr. Jodi
Nunnari (University of California, Davis). All cells were seeded on
#1.5 glass coverslips 2 to 4 days prior imaging or fixation.
Hippocampal neurons were isolated and cultured as previously
described(Tiscione et al, 2019). Briefly, hippocampi were dissected
from E18 mouse embryos and treated for 20 min at 37°C in Hank’s
solution containing 0.25% trypsin, followed by mechanical dissociation. Isolated neurons were plated on coverslips coated with poly-Llysine and cultured in Neurobasal supplemented with B27, Glutamax, 5% FBS, and 0.2% penicillin/streptomycin. After 7 days
in vitro (DIV), cytosine-D-arabinofuranoside (251010; Millipore)
was added to neuronal cultures to inhibit astrocyte growth. For inhibition of NPC1 activity and SREBP pathway, cells were treated for
24 h prior imaging with 10 µM U18666A and/or 10 µM PF-429242,
respectively.
Plasmid and sgRNA transfections
Plasmids encoding the following proteins were used: P4M-YFP
(Kruse et al, 2016), mCherry-P4M (Hammond et al, 2014), eGFPP4M (Hammond et al, 2014), GFP-tagged PI4KΙΙa and PI4KΙΙΙb (kind
gift from Tamas Balla, NIH, Bethesda, MD) (Balla et al, 2002), HAtagged DHHC3, DHHC3 (C157S), DHHC7, DHHC7 (C160S) and GSD
(kindly provided by M. Fukata, National Institute for Physiological
Sciences, Okazaki, Japan) (Fukata et al, 2004), pLAMP1-mCherry,
pLAMP1-mGFP, OSH1-GFP (Szentpetery et al, 2010), 2xFLAGSREBP-1a (Addgene: 26801), Str-Golgin84_VSVG-SBP-EGFP, StrKDEL_TNF-SBP-mCherry (Boncompain et al, 2012). In addition,
GFP-DHHC3 (Accession No: NM_016598.3) and GFP-ACBD3
(NM_022735.4) were cloned into pcDNA3.1(+)-N-eGFP: 50 : cloning
site KpnI, 30 Cloning Site: BamHI. Transfections of cDNAs (0.5 to
1 µg) were performed 24 h prior imaging using either Lipofectamine
2000 for hippocampal neurons, CHO and tsA201 cells, or Lipofectamine LTX for fibroblasts. To generate gene knockouts, short guide
RNAs targeting PI4KIIa, PI4KΙΙΙb, DHHC3, and ACBD3 were transfected in Cas9-expressing HEK293 cells along with a fluorescent
transfection marker using Lipofectamine RNAiMAX and incubated
for 48–72 h before imaging. Reduction in gene products was validated by Western blot and immunofluorescence analysis (Fig EV3).
A limitation of this approach is that it does not generate knockout
cell lines rather results in 70–90% knockdown of protein products.
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Immunofluorescence labeling
Cells were fixed for 10 min at room temperature in PBS with 3%
paraformaldehyde and 0.1% glutaraldehyde and blocked for 1 h in
50% SEA BLOCK Blocking Buffer and 0.5% Triton X-100 in PBS.
After 5 × 5 min washes in PBS washes, cells were incubated overnight at 4°C in 20% SEA BLOCK and 0.5% Triton X-100 in PBS with
the following primary antibodies: rabbit polyclonal PI4KIIa (1:250,
kindly provided by Pietro De Camilli, Yale University School of
Medicine, New Haven, CT), mouse monoclonal PI4KIIa (1:50),
mouse monoclonal PI4KIIIb (1:25), sheep polyclonal TGN46
(1:100), mouse monoclonal TGN46 (1:400), mouse monoclonal
EEA1 (1:25), mouse monoclonal RAB7 (1:50), rabbit polyclonal
OSBP (1:100), mouse monoclonal VAPA (hybridoma culture supernatant: 1:5; kindly provided by J. Trimmer, UC Davis, Davis, CA),
rabbit polyclonal DHHC3 (1:50), rabbit polyclonal SAC1 (1:100),
mouse monoclonal ACBD3 (1:50), mouse monoclonal Giantin
(1:500), rabbit polyclonal Giantin (1:100), rabbit polyclonal Lamp2
(1:00), and mouse monoclonal Lamp1 (1:20). For immunofluorescence detection, cells were incubated with Alexa Fluor 488 antirabbit (1:1,000), Alexa Fluor 555 anti-Sheep (1:1,000), and Alexa
Fluor 647 anti-mouse (1:1,000) secondary antibodies for 1 h at room
temperature in the dark.
Super-resolution confocal microscopy
Imaging was conducted at room temperature with a Zeiss LSM880
confocal laser scanning microscope equipped with a PlanApochromat 63× Oil DIC M27 objective (N.A. 1.4) and a superresolution Airyscan detection unit. Images of GFP/Alexa-488, YFP,
mCherry, and Alexa-647 were collected using the 488, 514, 594, and
633 nm excitation lines, respectively, with multicolor images
sequentially acquired. Live and fixed cells were imaged in PBS or
Ringer’s solution (in mM, 160 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10
HEPES, and 8 D-Glucose). For all acquisitions, images were taken at
0.5 µm depth intervals within the cell and were subsequently
corrected using the Airyscan processing toolbox in ZEN software.
Analysis was carried out with ImageJ (NIH, Bethesda, MD, USA).
Briefly, z-stack images were collapsed to single maximum intensity
projection images. After background subtraction, mean fluorescence
intensity was measured within a region of interest (ROI) and
normalized to the cytoplasm mean fluorescence intensity. For colocalization / overlap analyses, binary masks of TGN38/46, Giantin,
or Lamp1 images were used to measure P4M, PI4K enzymes, VAPA,
OSBP, SAC1, and SEC61b fluorescence intensities.
RUSH trafficking assay
Membrane trafficking was assessed by means of the retention using
selective hooks (RUSH) system (Boncompain et al, 2012). Briefly,
live imaging in tsA201 cells expressing Str-KDEL_TNF-SBP-mCherry
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or Str-Golgin84_VSVG-SBP-EGFP was performed using a combined
Andor W-1 spinning disk confocal microscope and Olympus Cell
total internal reflected fluorescence (TIRF) system, equipped
with a Photometrics Prime 95B camera and a stage-top temperature and CO2-controlled incubator (Okolab). Cells were excited
either with 488-nm or 561-nm lasers, and confocal or TIRF
images were collected through a 63× (1.4 NA) Olympus objective, using Micromanager software. All images were acquired at
37°C in phenol red-free DMEM with a frequency of 2 frames per
min. D-Biotin (80 lM) was added in the experimental chamber
after 1–2 min of acquisition. Image analysis was performed
using ImageJ software.
Quantitative polymerase chain reaction
The RNA transcripts from control and NPC1 patient fibroblasts were
first extracted using RNeasy Plus Mini Kit before being converted
into cDNA with an AffinityScript qPCR cDNA Synthesis Kit. Quantitative real-time PCR was performed in triplicate using the PowerUp
SYBR Green Master Mix. The following pre-made 5’ nuclease assays
were used: PI4K2A (Hs.PT.58.733616); PI4KB (Hs.PT.58.14990511);
ACBD3 (Hs.PT.58.26724987); ZDHHC3 (Hs.PT.58.45384099); HPRT
(Hs.PT.58v.45621572). HPRT was used as a reference to normalize
PCR products.
Western blotting
Patient fibroblasts, HEK293 Cas9, and tsA201 cells were homogenized on ice in RIPA lysis buffer supplemented with complete Mini
protease inhibitor cocktail. After centrifugation (20,400 g, 4°C,
25 min), the concentration of protein lysates in the supernatant was
determined using Pierce BCA Protein Assay Kit. Protein samples
were separated on 4 to 12% polyacrylamide Bis-Tris gel for 1h15 at
155V and electrophoretically blotted onto polyvinylidene difluoride
membranes using a Mini-Bolt system (A25977; Thermo Fisher
Scientific). After 1 h incubation at room temperature in TBS buffer
supplemented with 0.05% Tween-20 (TBS–T) and 7% non-fat dry
milk, membranes were exposed overnight at 4°C to the following
primary antibodies in TBS-Tween-20 0.05%: mouse monoclonal bactin, GAPDH, rabbit polyclonal PI4KΙIa, rabbit polyclonal PI4KΙΙΙb,
rabbit polyclonal OSBP, rabbit polyclonal SAC1, mouse monoclonal
ACBD3. Membranes were washed in TBS-Tween-20 0.05% and
incubated for 1 h at room temperature with fluorescent secondary
antibodies: goat anti-rabbit 680RD and goat anti-Mouse 800CW.
Signals were detected using Sapphire Gel Imager (Azure Biosystems) and quantified using ImageJ software.
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sample were normalized to synthetic standards and further
corrected for tissue amount using total protein.
Statistical analysis
Statistical analysis was performed using GraphPad Prism, version
8.4 (GraphPad Software, San Diego, California USA). All the data
values are presented as means  SEM. Number of technical and
biological replicates is based on previously published observations
and is consistent with the general number of replicates and conditions commonly accepted in the field. Data were assessed for
normality of distribution using a D’Agostino & Pearson test and
potential outliers were identified using a two-sided Grubbs’ test,
with an alpha value of 0.05, to determine whether values within a
dataset have significant outliers. Analyses containing excluded
values are noted in the figure legends. Statistical significance was
determined using appropriate unpaired two-tailed Student’s t-test,
nonparametric tests (Mann–Whitney), or one-way/two-way analysis
of variance (ANOVA) for multiple comparisons with appropriate
post hoc test. P < 0.05 was considered statistically significant
(*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.001).

Data availability
Lipid mass spectrometry data produced in this study are available at
MetaboLights database with the following ID: MTBLS2612 (http://
www.ebi.ac.uk/metabolights/MTBLS2612).
Expanded View for this article is available online.
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Lipid mass spectrometry
Phosphoinositide levels were quantified by a refined mass spectrometry procedure, as described previously (Traynor-Kaplan et al, 2017;
Vivas et al, 2019). Briefly, endogenous lipids from brain samples
and internal standards were extracted with n-butanol and chloroform. After methylation-mediated derivatization, samples were
subjected to a C4 column in an acetonitrile formic acid gradient.
Post-column eluate was infused with sodium formate and then
monitored by a Waters XEVO TQ-S MS/MS in multiple reaction
monitoring mode (MRM) using electrospray and positive ion mode.
Total integrated areas under peaks from sample and standard
elution profiles were quantified using MassLynx software. Peak
areas of individual phosphoinositide species from the biological
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